Tenet Healthcare (NYSE:THC) Announces Quarterly Earnings Results

Tenet Healthcare (NYSE:THC) released its quarterly earnings results on Friday. The company reported $6.12 earnings per share for the quarter, topping the consensus estimate of $4.26 by $1.86, FiscalAI reports. The firm had revenue of $6.04 billion for the quarter, compared to analysts’ expectations of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 27.17%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.02 earnings per share.

Here are the key takeaways from Tenet Healthcare’s conference call:

• Tenet raised its full-year 2026 outlook, increasing adjusted EBITDA guidance to $4.83 billion-$5.03 billion and boosting adjusted free cash flow after NCI to $1.825 billion-$2.055 billion.
• The company posted a strong second quarter, with revenue of $5.6 billion, adjusted EBITDA of $1.304 billion, and adjusted diluted EPS up 52% year over year to $6.12.
• USPI continued to outperform, delivering $542 million of adjusted EBITDA and 5% same-facility revenue growth, supported by higher-acuity procedures such as 10% growth in total joint replacements.
• The hospital segment also beat expectations, with adjusted EBITDA up 22% to $762 million and margins at 18%, but management emphasized that growth was helped by supplemental Medicaid favorability and operational improvements.
• Exchange-related pressures remain a headwind, with exchange revenues down 17% and admissions down about 13.5%, especially in states like Florida, Arizona, Michigan, South Carolina, and Texas.

Tenet Healthcare Price Performance

Shares of Tenet Healthcare stock opened at $233.10 on Friday. The business’s 50-day moving average price is $185.16 and its 200-day moving average price is $197.62. The firm has a market capitalization of $20.08 billion, a PE ratio of 8.99, a price-to-earnings-growth ratio of 1.93 and a beta of 1.27. Tenet Healthcare has a 12 month low of $146.60 and a 12 month high of $247.21. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96.

Key Headlines Impacting Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Tenet beat Q2 expectations by a wide margin, reporting $6.12 EPS versus estimates around $4.26, while revenue of $6.04 billion also came in above forecasts. The company cited strong same-store revenue growth and effective expense management. Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook
• Positive Sentiment: Management raised FY 2026 EPS guidance to $20.30-$21.69, well above prior Street expectations, signaling that the earnings beat may not be a one-quarter event. Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook
• Positive Sentiment: Investor enthusiasm was further supported by commentary highlighting hospital growth, expense control, and M&A momentum, with multiple reports describing the quarter as a “blockbuster” and noting the stock’s strong response. Tenet’s Blockbuster Quarter Sends Stock Flying, 2026 Outlook Gets Major Upgrade
• Neutral Sentiment: Tenet’s earnings call transcript and presentation may provide more detail on the quarter and outlook, but the main stock driver today appears to be the earnings beat and guidance increase rather than any new strategic surprise. Tenet Healthcare Corporation (THC) Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Media coverage also noted broader strength in hospital stocks, which may be adding to the move in Tenet Healthcare (THC). Why Tenet Healthcare Stock Is Soaring Today

Insider Activity at Tenet Healthcare

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director directly owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. This trade represents a 25.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Nadja West sold 3,000 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the sale, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.97% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

Several institutional investors have recently bought and sold shares of THC. Triumph Capital Management purchased a new position in Tenet Healthcare in the 3rd quarter worth approximately $25,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tenet Healthcare during the second quarter valued at approximately $35,000. Meeder Asset Management Inc. grew its holdings in shares of Tenet Healthcare by 146.2% in the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after purchasing an additional 114 shares during the last quarter. Geneos Wealth Management Inc. increased its stake in shares of Tenet Healthcare by 50.9% in the second quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock worth $46,000 after buying an additional 89 shares during the period. Finally, Wilkerson Advisory Group LLC purchased a new stake in Tenet Healthcare during the 4th quarter valued at $62,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on THC. UBS Group restated a “buy” rating on shares of Tenet Healthcare in a research note on Friday. Weiss Ratings lowered Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 2nd. Morgan Stanley set a $254.00 price objective on shares of Tenet Healthcare in a research report on Friday, May 1st. KeyCorp dropped their target price on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, Wall Street Zen raised shares of Tenet Healthcare from a “hold” rating to a “buy” rating in a report on Sunday. Seventeen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $246.47.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.